Sonoma Pharmaceuticals (SNOA) Cash from Financing Activities (2010 - 2025)

Sonoma Pharmaceuticals' Cash from Financing Activities history runs 16 years deep, the most recent figure standing at $210000.0 for Q4 2025.

• In Q4 2025, Cash from Financing Activities fell 70.34% year-over-year to $210000.0; the TTM figure through Dec 2025 stood at $332000.0 (down 90.26% YoY), while the FY2025 annual figure was $3.0 million, up 80.79% from the prior year.
• Cash from Financing Activities was $210000.0 for Q4 2025 at Sonoma Pharmaceuticals, up from -$62000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $6.9 million in Q3 2021 to a low of -$387000.0 in Q2 2022.
• Historically, Cash from Financing Activities has averaged $747500.0 across 5 years, with a median of $232000.0 in 2022.
• The sharpest annual moves came in 2021 and 2022: Cash from Financing Activities soared 3148.83% in 2021, then slumped 168.68% in 2022.
• A 5-year view of Cash from Financing Activities shows it stood at $463000.0 in 2021, then tumbled by 168.68% to -$318000.0 in 2022, then soared by 514.47% to $1.3 million in 2023, then plunged by 46.28% to $708000.0 in 2024, then tumbled by 70.34% to $210000.0 in 2025.
• The last three Cash from Financing Activities figures came in at $210000.0 (Q4 2025), -$62000.0 (Q3 2025), and -$58000.0 (Q2 2025), per Business Quant data.